Telix Is Paying $1.65 Billion for ITM Without Handing the Sellers Any Cash at Closing
- Telix Pharmaceuticals agreed on 21 September 2026 to acquire all of ITM Isotope Technologies Munich for $1.65bn upfront on a cash-free, debt-free basis, plus up to $700m in contingent payments tied to ITM-11. Telix shareholders will own about 76.3% of the combined company and ITM’s owners about 23.7%.
- ITM produces therapeutic radioisotopes including lutetium-177, actinium-225 and terbium-161, and distributes to more than 65 countries. Its audited 2025 revenue was $273m, after compound annual growth of 40% from 2021. Telix describes it as the only producer of globally scaled, commercial-grade lutetium-177.
- ITM-11 (177Lu-edotreotide) completed the Phase 3 COMPETE trial in gastroenteropancreatic neuroendocrine tumours, published in The Lancet in July 2026. The COMPOSE expansion study is fully enrolled, with a read-out expected in the first half of 2027.
- The companies project unaudited pro forma 2026 revenue and income above $1.3bn and a positive EBITDA contribution from 2027. Holders of more than 90% of ITM’s shares have approved, Telix shareholders vote at an extraordinary meeting expected in November, and closing is targeted by the end of FY2026.
Deal read
The headline is enterprise value. What the sellers actually receive at closing is Telix paper, locked up, and what they receive later depends on a dated regulatory calendar and one year of sales.
- No cash reaches the sellers at closing. Of the $1.65bn, $1.25bn is 105.8 million Telix shares priced at a 30-day average of $11.84, $302m is net debt Telix assumes, and $96m covers management rollover and expenses borne by the sellers. The shares sit in escrow for up to 15 months before release as Nasdaq ADRs, so ITM’s owners are buying into the combined company rather than exiting.
- The earnout runs on a clock. $100m requires FDA approval of ITM-11 in G1 to G2 disease by 31 December 2027, a further $100m in G2 to G3 disease by the end of 2030, and $50m in lung NETs by the end of 2031. The largest piece, $450m or 64% of the contingent value, depends on ITM-11 net sales above $150m in FY2030 alone, and Telix can settle every milestone in shares.
- Telix is buying a supplier its rivals depend on. ITM describes itself as a key isotope supplier to commercially available radiopharmaceuticals, and Telix has no approved therapeutic of its own, so those customers are other companies. They now source a critical input from a competitor that claims the industry’s most extensive therapeutic pipeline, which makes supply contracts and any diversification by other lutetium users the thing to watch after closing.